| [Kidney transplantation: how shall we deal with marginal cases? Future prospects from basic research]. | |
| | |
MedLine Citation:
|
PMID: 20808071 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The research performed at the Department of Urology Osaka University Graduate School of Medicine is overviewed. Renal ischemia-reperfusion (I/R) injury is inevitable in transplantation and is related to longterm graft function. MF-1, a bifunctional hepatocyte growth factor-macrophage stimulating protein chimera, was found to prevent apoptosis. In our study, MF-1 directly guarded cultured proximal tubular epithelial cells from hypoxia-induced necrosis and apoptosis in vitro, and MF-1 treatment ameliorated renal dysfunction by preventing apoptosis in rat I/R injury model. The erythropoietin molecule modified by carbamylation (CEPO) has been identified and was demonstrated to protect several organs without increasing the hemoglobin concentration. The therapeutic effect of CEPO was evaluated using an endothelial tube formation assay, and a rat ischemia-reperfusion injury model. CEPO treatment induced more capillarylike formation than EPO. CEPO-treated kidneys showed minimal tubular apoptosis with increased peritubular capillary endothelial cells. We identified a new therapeutic approach using CEPO to protect the kidney from ischemia-reperfusion injury by promoting angiogenesis. |
| | |
Authors:
|
Naotsugu Ichimaru; Koji Yazawa; Shiro Takahara |
Publication Detail:
|
Type: English Abstract; Journal Article; Review |
Journal Detail:
|
Title: Hinyokika kiyo. Acta urologica Japonica Volume: 56 ISSN: 0018-1994 ISO Abbreviation: Hinyokika Kiyo Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-09-02 Completed Date: 2010-11-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0421145 Medline TA: Hinyokika Kiyo Country: Japan |
Other Details:
|
Languages: jpn Pagination: 481-4 Citation Subset: IM |
Affiliation:
|
Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cytokines / therapeutic use Erythropoietin / analogs & derivatives, therapeutic use Graft Survival / physiology* Hepatocyte Growth Factor / therapeutic use Humans Kidney Transplantation* Rats Recombinant Fusion Proteins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Recombinant Fusion Proteins; 0/carbamylated erythropoietin; 0/metron factor-1; 11096-26-7/Erythropoietin; 67256-21-7/Hepatocyte Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Renal protective effects of erythropoietin on ischemic reperfusion injury.
Next Document: Effects of low- and high-intensity exercise training on body composition and substrate metabolism in...